Cellular vamp cleavage assay
AssigneeIpsen Biopharm Ltd.
InventorsBryony Gray, Verity Cadd, Matthew Beard
Life of this patent
Estimating the term…
Loading patent…
AssigneeIpsen Biopharm Ltd.
InventorsBryony Gray, Verity Cadd, Matthew Beard
Estimating the term…
A method for determining cleavage of a VAMP by a clostridial neurotoxin in a cell that has been contacted with the clostridial neurotoxin under conditions suitable for clostridial neurotoxin activity, the method comprising contacting the cytoplasmic content of the cell with an antibody that binds to a resulting C-terminal product of such cleavage under suitable conditions in vitro or ex vivo and detecting the binding of the antibody to the C-terminal cleavage product. The antibody may, for example, be capable of binding an antigenic polypeptide consisting of 10 to 65 amino acid residues and comprising an epitope comprising an amino acid sequence that is at least 90% identical to an amino acid sequence of at least 8 amino acid residues that is immediately C-terminal to a clostridial neurotoxin cleavage site in the VAMP.
A method for determining cleavage in a cell of a VAMP into C-terminal and N-terminal cleavage products by a VAMP-cleaving clostridial neurotoxin, the method comprising:
Dependencies are inferred from the claim text.